Having demonstrated sensitization of tumor cells to genotoxic chemotherapeutic agents and tumoricidal activity by CLPTM1L inhibition, and with a lack of in vivo evidence in ovarian cancer models, we sought to determine if anti-CLPTM1L mAb treatment could inhibit ovarian carcinoma in relevant murine models, including a cisplatin resistant tumor model. The gene discussed is CLPTM1L; the disease is ovarian cancer.